EA202091087A1 - METHODS FOR REDUCING THE SIDE EFFECTS OF THERAPY WITH ANTIBODY AGAINST CD30-DRUG CONJUGATE - Google Patents

METHODS FOR REDUCING THE SIDE EFFECTS OF THERAPY WITH ANTIBODY AGAINST CD30-DRUG CONJUGATE

Info

Publication number
EA202091087A1
EA202091087A1 EA202091087A EA202091087A EA202091087A1 EA 202091087 A1 EA202091087 A1 EA 202091087A1 EA 202091087 A EA202091087 A EA 202091087A EA 202091087 A EA202091087 A EA 202091087A EA 202091087 A1 EA202091087 A1 EA 202091087A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
drug conjugate
therapy
reducing
side effects
Prior art date
Application number
EA202091087A
Other languages
Russian (ru)
Inventor
Томас Мэнли
Нэил Джозефсон
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Priority claimed from PCT/US2018/058613 external-priority patent/WO2019089870A1/en
Publication of EA202091087A1 publication Critical patent/EA202091087A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение в целом относится к способам улучшения нежелательных явлений у субъектов с лимфомой из зрелых Т-клеток, получающих лечение конъюгатом "антитело против CD30-лекарственное средство" в комбинации с сопутствующей химиотерапией. Нежелательные явления включают периферическую невропатию и нейтропению.The present invention generally relates to methods for ameliorating adverse events in subjects with mature T cell lymphoma receiving anti-CD30 antibody drug conjugate treatment in combination with concomitant chemotherapy. Adverse events include peripheral neuropathy and neutropenia.

EA202091087A 2018-10-01 2018-11-01 METHODS FOR REDUCING THE SIDE EFFECTS OF THERAPY WITH ANTIBODY AGAINST CD30-DRUG CONJUGATE EA202091087A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739635P 2018-10-01 2018-10-01
PCT/US2018/058613 WO2019089870A1 (en) 2017-11-01 2018-11-01 Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy

Publications (1)

Publication Number Publication Date
EA202091087A1 true EA202091087A1 (en) 2020-09-21

Family

ID=72615976

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091087A EA202091087A1 (en) 2018-10-01 2018-11-01 METHODS FOR REDUCING THE SIDE EFFECTS OF THERAPY WITH ANTIBODY AGAINST CD30-DRUG CONJUGATE

Country Status (1)

Country Link
EA (1) EA202091087A1 (en)

Similar Documents

Publication Publication Date Title
BRPI0516531A (en) autoimmune disorders immunotherapy
MA47313B1 (en) Her2 antibody subcutaneous formulations
MX2020010907A (en) Enhancement of delivery of lipophilic active agents across the blood-brain barrier and methods for treating central nervous system disorders.
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
MX2021006681A (en) Anti-claudin antibodies and uses thereof.
MA39094A1 (en) Combination therapy comprising an inhibitor of mdm2 and one or more additional pharmaceutically active principles for the treatment of cancers
EA201892657A1 (en) SPYROLACTAM MODULATORS OF THE NMDA-RECEPTOR AND THEIR APPLICATION
MX2020005217A (en) Ophthalmic composition and delivery device thereof.
RU2017134443A (en) METHOD OF TREATMENT WITH USE OF TRADIPTANT
RU2014150942A (en) TREATMENT OF SIDE EFFECTS IN THE FORM OF MOTOR AND MOTOR DISORDERS RELATED TO THE TREATMENT OF PARKINSON'S DISEASE
MX2021002321A (en) Novel methods.
PH12020551726A1 (en) Treatment of atopic dermatitis
MX2022000143A (en) Novel methods.
MX2021002322A (en) Novel methods.
MX2023000187A (en) Dosing of vibegron for treatment of overactive bladder.
MX2020004563A (en) Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy.
EA202190457A1 (en) CONJUGATES FOR USE IN METHODS FOR TREATMENT OF CANCER
WO2017181099A8 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
EA202091751A1 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
EA202091087A1 (en) METHODS FOR REDUCING THE SIDE EFFECTS OF THERAPY WITH ANTIBODY AGAINST CD30-DRUG CONJUGATE
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
EA202193178A1 (en) METHODS FOR TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA USING DEUTERATED DEXTROMETHORPHAN AND QUINIDINE
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity